ADDF
Stories
-
Biogen presents new two-year data from Phase 2 CELIA study of diranersen
Biogen reported a 38% slowing of decline at two years on CDR-SB with the lowest dose of diranersen, up from 26% at 18 months. No new safety signals were reported for that dose.